Anbio Biotechnology (NNNN) stock
NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$3.60−0.05 (-1.37%)
Close on Nov 18, 2026Market cap $518.01MP/E 24.5Yield –
Anbio Biotechnology revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was $8.65M, up 5.6% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.65M | +5.6% |
| FY2024 | Dec 31, 2024 | $8.19M | +21.9% |
| FY2023 | Dec 31, 2023 | $6.71M | -71.5% |
| FY2022 | Dec 31, 2022 | $23.54M | – |
See a number that looks wrong?